Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, built on the immune peptide tuftsin with a Pro-Gly-Pro tail, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered in Russia as an anxiolytic nasal drop. It is the second of the two Russian nootropic peptides on this site, beside Semax, and it is a case where a label exists but answers a different question from the one searched: the label doses in drops, the research market sells a powder in 5 mg and 10 mg vials, and the figures that circulate are in micrograms. This page reports the label as it reads, converts it into micrograms with the assumption made visible, reports the three Russian trials and the circulating figures with their provenance, and does the syringe arithmetic for the two vial sizes. It recommends nothing.
The Selank calculator runs the same sums for any vial and volume, and the dosage hub indexes every compound this site covers. The N-acetylated, amidated variant sold as NA-Selank Amidate is a different molecule with its own calculator and is not covered here.
What the Russian label states
| Item | Selank, nasal drops 0.15% |
|---|---|
| Strength | 1.5 mg per mL; 4.5 mg per 3 mL bottle |
| Regimen | 2 drops into each nasal passage, 3 times a day |
| Course | 14 days; repeatable after 1 to 3 weeks on a physician's advice |
| Route | intranasal only; the bottle carries a dropper cap |
| Bioavailability | 92.8% absolute, by the nasal route |
| Shelf life | 2 years |
| Registration | LP-No.(010951)-(RG-RU), last amended 2025-07-15; previously LSR-003338/09 |
| Holder and manufacturer | AO INPTs Peptogen, Moscow |
| ATC code | N05BX, other anxiolytics |
Source: the register entry and instruction on rlsnet.ru, read 2026-09-18; the Vidal entry, read the same day, agrees on the strength, the bottle and the registration. The label gives the dose in drops throughout and states no microgram figure anywhere.
The label in micrograms, with the assumption shown
A drop is not a unit of mass, so any microgram figure for the labelled regimen rests on a drop size. At the conventional pharmaceutical figure of 20 drops per millilitre, one drop is 0.05 mL, and 0.05 mL of a 1.5 mg/mL solution is 75 mcg. Two drops per nostril is four drops, or 300 mcg per administration; three administrations is 12 drops, or 900 mcg per day; a 14-day course is 8.4 mL, nearly three of the 3 mL bottles. The 900 mcg per day figure that circulates is exactly this arithmetic. It is a fair reading of the label, and it is not on the label; a dropper that delivers a larger or smaller drop moves every figure with it.
What the trials report
| Trial (all in Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova) | Patients | Comparator | Dose stated in the abstract |
|---|---|---|---|
| Zozulya and colleagues, 2008 (PMID 18454096) | 62 with generalised anxiety disorder or neurasthenia; 30 on Selank | medazepam (32) | none |
| Medvedev and colleagues, 2014 (PMID 25176261) | 60 with anxiety-phobic and somatoform disorders | phenazepam | none |
| Medvedev and colleagues, 2015 (PMID 26356395) | 70; 40 on Selank added to phenazepam, 30 on phenazepam alone | phenazepam monotherapy | none |
The three are the only Selank records PubMed tags as clinical trials among 68 in total (read 2026-09-18). The 2008 abstract reports anxiolytic effects similar to medazepam with added antiasthenic effects; the 2014 abstract reports an anxiolytic effect lasting a week after the last dose; the 2015 abstract reports fewer benzodiazepine side effects in the combination group. None of the abstracts states what dose was given, so the label's regimen is the only figure with a source, and it is the figure the trials presumably used.
The figures that circulate
Vendor and forum pages read on 2026-09-18 cited 250 to 3,000 mcg per day intranasally, most often 400 to 600 mcg two or three times a day; 250 to 500 mcg subcutaneously; and courses of two to three weeks followed by a break. The label's implied 900 mcg per day sits inside the intranasal range. The subcutaneous figures have no source at all: no injectable Selank product is registered anywhere that could be found, the trials used the nasal product, and the label's bioavailability figure describes nasal absorption, not injection. Peptifact's Selank page reads the same sources from the journalism side.
The arithmetic per vial
Concentration in mcg/mL is the vial amount divided by the water volume; micrograms per unit is that figure divided by 100, because a U-100 syringe holds 100 units in 1 mL and each small notch on a standard 1 mL insulin syringe is 1 unit (MedlinePlus, reviewed 2024-07-21). The columns are the label's implied 300 mcg administration, its 900 mcg day, and the circulating 250 and 500 mcg figures; they are converted, not endorsed. Because Selank amounts are small, the calculator notes on this site observe that more water gives larger, more readable draws.
| Vial and water | mcg/mL | mcg per unit | 250 mcg | 300 mcg | 500 mcg | 900 mcg |
|---|---|---|---|---|---|---|
| 5 mg in 1 mL | 5,000 | 50 | 5 units | 6 | 10 | 18 |
| 5 mg in 2 mL | 2,500 | 25 | 10 | 12 | 20 | 36 |
| 5 mg in 3 mL | 1,667 | 16.7 | 15 | 18 | 30 | 54 |
| 10 mg in 1 mL | 10,000 | 100 | 2.5 | 3 | 5 | 9 |
| 10 mg in 2 mL | 5,000 | 50 | 5 | 6 | 10 | 18 |
| 10 mg in 3 mL | 3,333 | 33.3 | 7.5 | 9 | 15 | 27 |
A 5 mg vial holds five label-sized days of 900 mcg or sixteen 300 mcg administrations with 200 mcg left; a 10 mg vial holds twice as many. Where a reconstituted vial is loaded into a metered nasal spray rather than a syringe, the same concentration sets the micrograms per actuation, and the calculator's mcg/mL figure is the number that matters; this page does not describe how that is done.
What the figures omit
The label figure carries a route (intranasal), a population (adults with anxiety disorders, in Russian practice), a duration (14 days) and a form (a 0.15% solution with a methylparaben preservative). The trial figures carry a Russian-language literature, comparators that are benzodiazepines, and abstracts that do not state the dose. No injectable data, no Western registration, no pharmacokinetics by injection and no safety data beyond the Russian trials exist in the sources opened. The mechanism, the evidence file and the sourcing belong to Medibact's Selank guide.
Status outside Russia
No approval outside Russia could be found on 2026-09-18: DailyMed holds no record, and no ClinicalTrials.gov registration uses Selank as an intervention. In the United States FDA placed Selank acetate (TP-7) in Category 2 of its section 503A bulk-substance list on 2023-09-29, the category for substances FDA says raise significant safety risks (list read 2026-09-18). When FDA sent seven peptides to its Pharmacy Compounding Advisory Committee for July 2026, Selank was not among them (Federal Register document 2026-07361, 2026-04-16), so its status did not move with theirs.
Sources and dates
Opened 2026-09-18: the Russian register entry and instruction on rlsnet.ru and the Vidal listing for Selank nasal drops 0.15%; DailyMed (no record); ClinicalTrials.gov v2 API (no interventional registration); PubMed, with the abstracts of PMIDs 18454096, 25176261 and 26356395 read in full; FDA's 503A category list dated 2023-09-29; Federal Register document 2026-07361; MedlinePlus, "Giving an insulin injection" (reviewed 2024-07-21); vendor and forum pages for the circulating figures. Vial sizes are the ones the calculator preset uses.
This page does not recommend a dose, a route, a frequency or a schedule, and it does not say what any figure means for a particular person. It reports a Russian label, three trials and the figures that circulate, states the one assumption that turns drops into micrograms, and converts micrograms into syringe units.